심근유래의 줄기세포 프라이밍 및 조직공학 기술에 의한 심혈관 재생전략 (Cell Priming and Tissue Engineering Strategies for Cardiovascular Regeneration Using Human Heart Tissue-Derived Cardiac Progenitor Cells (hCPCs))

서지정보

· 발행기관 : 한국생물공학회
· 수록지 정보 : KSBB Journal / 33권 / 3호 / 127 ~ 134페이지
· 저자명 : 박지혜, 김희정, 정한나, 박혜리, 황혜원, 권상모

초록

The prevalence and mortality rate of cardiovascular disease continue to increase despite the development of new drugs and treatments. Stem cell therapy is a promising strategy to repair and/or regenerate damaged cardiac tissue. Cardiac progenitor cells may be stronger candidates than other stem cells for cardiac cell therapy. Cardiac progenitor cells (CPCs) residing in the heart (also referred to as cardiosphere-derived cells (CDCs) exert a therapeutic potential in repairing heart damage. Numerous studies have identified candidate CPC cell surface markers, including c-kit, stem cell antigen 1 (Sca1), and platelet-derived growth factor receptor α (PDGFRα).
CPCs are capable of differentiating into multiple mature cardiac cell types, including cardiomyocytes (CM), smooth muscle cells (SMC), and endothelial cells (EC). Owing to their unique pluripotency, various pre-clinical and clinical studies are being conducted using cardiac progenitor cells to regenerate damaged heart tissues. However, poor stem cell survival and low engraftment efficiency underlie significant reductions in therapeutic efficacy. To overcome current limitations that reduce stem cell therapeutic efficacy, many methods have been implemented that aim to improve stem cell survival and engraftment.
Recently, stem cell priming and tissue engineering technologies have been suggested to enhance stem cell therapeutic efficacy. It is possible to increase survival and engraftment of cardiac progenitor cells in injured cardiac tissue by cell priming and tissue engineering technologies before use. In this review, we provide an understanding of multiple therapeutic approaches including cell priming, scaffolds, tissue engineering, 3D printing techniques and clinical prospect for cardiovascular regeneration using patient-derived CPCs

영어초록

The prevalence and mortality rate of cardiovascular disease continue to increase despite the development of new drugs and treatments. Stem cell therapy is a promising strategy to repair and/or regenerate damaged cardiac tissue. Cardiac progenitor cells may be stronger candidates than other stem cells for cardiac cell therapy. Cardiac progenitor cells (CPCs) residing in the heart (also referred to as cardiosphere-derived cells (CDCs) exert a therapeutic potential in repairing heart damage. Numerous studies have identified candidate CPC cell surface markers, including c-kit, stem cell antigen 1 (Sca1), and platelet-derived growth factor receptor α (PDGFRα).
CPCs are capable of differentiating into multiple mature cardiac cell types, including cardiomyocytes (CM), smooth muscle cells (SMC), and endothelial cells (EC). Owing to their unique pluripotency, various pre-clinical and clinical studies are being conducted using cardiac progenitor cells to regenerate damaged heart tissues. However, poor stem cell survival and low engraftment efficiency underlie significant reductions in therapeutic efficacy. To overcome current limitations that reduce stem cell therapeutic efficacy, many methods have been implemented that aim to improve stem cell survival and engraftment.
Recently, stem cell priming and tissue engineering technologies have been suggested to enhance stem cell therapeutic efficacy. It is possible to increase survival and engraftment of cardiac progenitor cells in injured cardiac tissue by cell priming and tissue engineering technologies before use. In this review, we provide an understanding of multiple therapeutic approaches including cell priming, scaffolds, tissue engineering, 3D printing techniques and clinical prospect for cardiovascular regeneration using patient-derived CPCs

참고자료

· 없음